Interviews

Sandra Stein, MD, of Banner Health Plans, details how she provides clinical and medical leadership in her role as chief medical officer.

Brian Mullen, PhD, head of innovation and product at The Clinic by Cleveland Clinic, discusses how providing second opinions has improved patient and provider experiences in health care.

Jeff McIntyre, MA, of the Global Liver Institute (GLI), discusses the importance of the health care community understanding non-alcoholic steatohepatitis (NASH) and how to mitigate its global impact.

Ian Neeland, MD, of University Hospitals Harrington Heart & Vascular Institute, talks about the uptick in patients at his practice seeking semaglutide for weight loss.

Especially during shortages, Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, director of pharmacy services at Minnesota Oncology, says practices should carve out areas where going to a different therapeutic approach isn't considered off-pathway.

According to Sandra Stein, MD, of Banner Health Plans, the event highlighted the significant influence of social determinants of health on health care costs and outcomes, emphasizing the shift in focus from traditional medical care to addressing crucial factors like housing, food, transportation, and utilities for positive health outcomes.

Bevey Miner, executive vice president of health care strategy and policy, Consensus Cloud Solutions, shares how extraction artificial intelligence is helping train machine learning models to recognize and extract information from documents, providing structured data with confidence scores.

Michael Gieske, MD, director of lung cancer screening at St. Elizabeth Health Care, speaks to the success of the Rural Appalachian Lung Cancer Screening Initiative, along with challenges to implementing increased lung cancer screening.

Sidney (Beau) Raymond, MD, MMM, FACP, chief medical officer of Ochsner Health Network, believes that the health care system should focus on preventing illness and disease, rather than just treating them after they occur.

Amrish Selvam is a fourth-year medical student at the University of Pittsburgh whose research and career interests lay in ophthalmology and who volunteers with the UPMC Vision Institute’s mobile eye clinic, the eyeVan.

Possible long-term consequences for patients with diabetes forced to switch to alternative medications during the semaglutide shortage include the risk of losing ground in glycemic control, having uncontrolled diabetes with associated symptoms, and other adverse events.

Elaine Siegfried, MD, of Saint Louis University School of Medicine, summarized the recent American Academy of Dermatology guideline update for atopic dermatitis (AD).

Edward "Ted" Arrowsmith, MD, MPH, medical director for pathways at OneOncology and managing partner at Tennessee Oncology, talks about challenges and changes in clinical pathways and the importance of keeping them updated.

A social-impact startup, Pittsburgh-based Fabric Health is adept at using community engagement to help members and their families navigate the complex world of health care—meeting customers where they are at, knowing time is often their most valuable resource.

According to Ian Neeland, MD, there are 2 main reasons for the shortage of injectable semaglutide: the fact that oral semaglutide has not yet been tested for weight loss, and that most practitioners just overlook it as an option.

Mike Brown, vice president of managed services at Cardinal Health, discusses how Cardinal Health has worked to integrate key digital health solutions among hospitals across the United States.

David Adamson, MD, founder and CEO of ARC Fertility, discusses how physicians should consider moral and ethical variations of patients when adhering to professional guidelines in fertility care.

Ed Clarke, MD, of Banner Health weighs in on whether health systems should invest in the social determinants of health.

Ian Neeland, MD, highlights that oral semaglutide is more accessible and that patients should avoid switching drug types during the shortage.

Margaret Liang, MD, MSHPM, gynecologic oncologist and health services researcher and director, Gynecologic Oncology Fellowship Program, Cedars-Sinai Cancer Center, discusses financial toxicity in cancer care and how institutions can help alleviate the financial burden for patients.

Melinda C. Aldrich, PhD, MPH, associate professor in the departments of medicine, thoracic surgery, and biomedical informatics at Vanderbilt University, discussed recently updated lung screening guidelines from the American Cancer Society and the importance of equity across populations as new guidelines are developed.

Kimberly Westrich, MA, of the National Pharmaceutical Council, explained how she envisions value assessment tools to be used in the US health care system in coming years.

Michael Gieske, MD, director of lung cancer screening at St. Elizabeth Health Care, discusses disparities in lung cancer incidence and mortality that the Rural Appalachian Lung Cancer Screening Initiative aims to address.

In this interview with Katie Cecconi, community service program coordinator at the UPMC Vision Institute, we learn more about the institute’s mobile eye care initiatives and how its services are working to overcome care equity gaps.

Jonathan Silverberg, MD, PhD, MPH, of George Washington University School of Medicine and Health Sciences, explains the benefits of using Janus kinase (JAK) inhibitors to treat patients with atopic dermatitis (AD).

Amy Laughlin, MD, MSHP, of Orlando Health commented on at-home cancer care costs and shared her predictions on how at-home cancer care will evolve.

Ian Neeland, MD, of University Hospitals Harrington Heart & Vascular Institute, describes challenges patients with diabetes face during the semaglutide shortage and alternative options he gives his patients to prevent therapy disruptions.

Kathi Mooney, PhD, RN, FAAN, of the University of Utah, discussed technologies she and her team developed to help improve the quality of life of patients with cancer and their families.

Andy Blauvelt, MD, MBA, president of Oregon Medical Research Center, recommends new novel topical therapies over topical steroids for patients with atopic dermatitis (AD).

Elaine Siegfried, MD, of Saint Louis University School of Medicine, discusses how the recent guideline update by the American Academy of Dermatology (AAD) affects dermatologists' atopic dermatitis (AD) treatment decisions.